Acorda Therapeutics, Inc. (ACOR)
Stock Price:
$0.707 USD
0.001 (0.16%)
Updated November 23, 10:58 AM EST - Market open
Key Info
| Market Cap |
33.92M |
| Revenue (ttm) |
165.30M |
| Net Income (ttm) |
49.11M |
| Shares Out |
47.96M |
| EPS (ttm) |
1.02 |
| PE Ratio |
0.69 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 23 |
| Last Price |
$0.707 |
| Previous Close |
$0.706 |
| Change ($) |
0.001 |
| Change (%) |
0.16% |
| Day's Open |
0.720 |
| Day's Range |
0.691 - 0.720 |
| Day's Volume |
624,581 |
| 52-Week Range |
0.422 - 2.780 |
More Stats
| Market Cap |
33.92M |
| Enterprise Value |
188.93M |
| Earnings Date (est) |
Feb 18, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
47.96M |
| Float |
47.12M |
| EPS (basic) |
1.02 |
| EPS (diluted) |
1.02 |
| FCF / Share |
-1.93 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
144.23% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.24M |
| Short Ratio |
0.90 |
| Short % of Float |
15.36% |
| Beta |
0.94 |
| PE Ratio |
0.69 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.21 |
| PB Ratio |
0.11 |
| Revenue |
165.30M |
| Operating Income |
-89.56M |
| Net Income |
49.11M |
| Free Cash Flow |
-91.97M |
| Net Cash |
-155.01M |
| Net Cash / Share |
-3.23 |
| Gross Margin |
95.31% |
| Operating Margin |
-54.18% |
| Profit Margin |
29.70% |
| FCF Margin |
-55.64% |
| ROA |
-6.37% |
| ROE |
16.51% |
| ROIC |
17.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
1 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$2.33*
(229.47% upside)
Low
1.00
Current: $0.707
High
5.00
Target: 2.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 192 | 471 | 588 | 520 | 493 | 401 | 336 | 306 | 292 | 191 |
| Revenue Growth | -59.19% | -19.86% | 13.22% | 5.47% | 22.71% | 19.34% | 10.01% | 4.65% | 53% | - |
| Gross Profit | 158 | 374 | 476 | 411 | 400 | 321 | 270 | 248 | 226 | 155 |
| Operating Income | -399 | 93.49 | -192 | -17.48 | 45.30 | 38.82 | 30.37 | 25.60 | 35.04 | -8.42 |
| Net Income | -273 | 33.68 | -223 | -34.62 | 11.06 | 17.67 | 16.44 | 155 | 30.61 | -11.77 |
| Shares Outstanding | 47.51 | 47.01 | 46.00 | 45.26 | 42.23 | 41.15 | 40.21 | 39.46 | 39.00 | 38.36 |
| Earnings Per Share | -5.75 | 0.71 | -4.86 | -0.76 | 0.25 | 0.42 | 0.39 | 3.84 | 0.76 | -0.31 |
| EPS Growth | - | - | - | - | -40.48% | 7.69% | -89.84% | 405.26% | - | - |
| Operating Cash Flow | -128 | 151 | 97.14 | 29.65 | 38.48 | 74.65 | 39.29 | 52.12 | 66.34 | -19.22 |
| Capital Expenditures | -90.43 | -33.33 | -13.69 | -6.19 | -5.92 | -5.08 | -4.04 | -10.38 | -2.19 | -2.45 |
| Free Cash Flow | -219 | 117 | 83.45 | 23.46 | 32.56 | 69.57 | 35.24 | 41.74 | 64.14 | -21.66 |
| Cash & Equivalents | 169 | 446 | 307 | 159 | 359 | 309 | 274 | 234 | 296 | 240 |
| Total Debt | 250 | 344 | 335 | 331 | 293 | 291 | 4.37 | 5.39 | 6.37 | 7.33 |
| Net Cash / Debt | -80.67 | 103 | -27.64 | -172 | 66.64 | 17.80 | 270 | 229 | 290 | 233 |
| Assets | 800 | 1,300 | 1,198 | 1,342 | 1,111 | 1,065 | 607 | 565 | 379 | 342 |
| Liabilities | 489 | 688 | 678 | 678 | 508 | 525 | 167 | 179 | 174 | 191 |
| Book Value | 311 | 612 | 520 | 664 | 603 | 540 | 440 | 386 | 205 | 151 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Acorda Therapeutics, Inc. |
| Country |
United States |
| Employees |
344 |
| CEO |
Ronald Cohen |
Stock Information
| Ticker Symbol |
ACOR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ACOR |
| IPO Date |
February 10, 2006 |
Description
Acorda Therapeutics, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.